8XK5

SNB1G11 Fab bound to SFTSV glycoprotein Gn

Summary for 8XK5

• Entry DOI: 10.2210/pdb8xk5/pdb
• Descriptor: mAb SNB1G11 Fab heavy chain, mAb SNB1G11 Fab light chain, Envelopment polyprotein (3 entities in total)
• Functional Keywords: glycoprotein, gn, fab, viral protein
• Biological source: Mus musculus; More
• Total number of polymer chains: 15
• Total formula weight: 464518.64

Authors

Deng, Z. (deposition date: 2023-12-22, release date: 2024-07-10, Last modification date: 2024-11-13)

Primary citation

Ren, X.,Sun, J.,Kuang, W.,Yu, F.,Wang, B.,Wang, Y.,Deng, W.,Xu, Z.,Yang, S.,Wang, H.,Hu, Y.,Deng, Z.,Ning, Y.J.,Zhao, H.
A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection.
Nat Commun, 15:7009-7009, 2024

PubMed Abstract: Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that causes severe viral hemorrhagic fever and thrombocytopenia syndrome with a fatality rate of up to 30%. No licensed vaccines or therapeutics are currently available for humans. Here, we develop seven monoclonal antibodies (mAbs) against SFTSV surface glycoprotein Gn. Mechanistic studies show that three neutralizing mAbs (S2A5, S1G3, and S1H7) block multiple steps during SFTSV infection, including viral attachment and membrane fusion, whereas another neutralizing mAb (B1G11) primarily inhibits the viral attachment step. Epitope binning and X-ray crystallographic analyses reveal four distinct antigenic sites on Gn, three of which have not previously been reported, corresponding to domain I, domain II, and spanning domain I and domain II. One of the most potent neutralizing mAbs, S2A5, binds to a conserved epitope on Gn domain I and broadly neutralizes infection of six SFTSV strains corresponding to genotypes A to F. A single dose treatment of S2A5 affords both pre- and post-exposure protection of mice against lethal SFTSV challenge without apparent weight loss. Our results support the importance of glycoprotein Gn for eliciting a robust humoral response and pave a path for developing prophylactic and therapeutic antibodies against SFTSV infection.

PubMed: 39147753
DOI: 10.1038/s41467-024-51108-z

Experimental method

X-RAY DIFFRACTION (3.05 Å)